Genomics and GSK to integrate polygenic risk scores into trials

Genomics has entered a partnership with GSK to evaluate the potential integration of polygenic risk scores (PRS) into clinical trial methodologies.

This innovative approach is expected to enhance the understanding of disease risk and refine subject selection, potentially leading to more efficient clinical trials.